Tenax Therapeutics Inc. (TENX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Tenax Therapeutics Statistics
Share Statistics
Tenax Therapeutics has 3.41M shares outstanding. The number of shares has increased by 93.03% in one year.
Shares Outstanding | 3.41M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 2.98M |
Failed to Deliver (FTD) Shares | 195 |
FTD / Avg. Volume | 0.29% |
Short Selling Information
The latest short interest is 105.76K, so 3.1% of the outstanding shares have been sold short.
Short Interest | 105.76K |
Short % of Shares Out | 3.1% |
Short % of Float | 3.55% |
Short Ratio (days to cover) | 1.46 |
Valuation Ratios
The PE ratio is -0.71 and the forward PE ratio is -0.96.
PE Ratio | -0.71 |
Forward PE | -0.96 |
PS Ratio | 0 |
Forward PS | 5.2 |
PB Ratio | 0.67 |
P/FCF Ratio | -0.92 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tenax Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 0.06.
Current Ratio | 3.26 |
Quick Ratio | 3.26 |
Debt / Equity | 0.06 |
Total Debt / Capitalization | 5.83 |
Cash Flow / Debt | -11.79 |
Interest Coverage | -343.55 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -95.75%.
Return on Equity (ROE) | -0.95% |
Return on Assets (ROA) | -0.66% |
Return on Capital (ROIC) | -95.75% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.54M |
Employee Count | 5 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -34.73% in the last 52 weeks. The beta is 2.15, so Tenax Therapeutics 's price volatility has been higher than the market average.
Beta | 2.15 |
52-Week Price Change | -34.73% |
50-Day Moving Average | 5.64 |
200-Day Moving Average | 4.14 |
Relative Strength Index (RSI) | 57.59 |
Average Volume (20 Days) | 67.41K |
Income Statement
Revenue | n/a |
Gross Profit | -7.57K |
Operating Income | -8.23M |
Net Income | -7.71M |
EBITDA | -8.23M |
EBIT | n/a |
Earnings Per Share (EPS) | -31.09 |
Balance Sheet
The company has 9.79M in cash and 500.90K in debt, giving a net cash position of 9.29M.
Cash & Cash Equivalents | 9.79M |
Total Debt | 500.90K |
Net Cash | 9.29M |
Retained Earnings | -297.25M |
Total Assets | 99.78M |
Working Capital | 97.22M |
Cash Flow
In the last 12 months, operating cash flow was -5.90M and capital expenditures 2.84K, giving a free cash flow of -5.90M.
Operating Cash Flow | -5.90M |
Capital Expenditures | 2.84K |
Free Cash Flow | -5.90M |
FCF Per Share | -23.8 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
TENX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -488.07% |
FCF Yield | -27.19% |
Analyst Forecast
The average price target for TENX is $16, which is 151.2% higher than the current price. The consensus rating is "Buy".
Price Target | $16 |
Price Target Difference | 151.2% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Stock Splits
The last stock split was on Jan 3, 2024. It was a backward split with a ratio of 1:80.
Last Split Date | Jan 3, 2024 |
Split Type | backward |
Split Ratio | 1:80 |
Scores
Altman Z-Score | 1.56 |
Piotroski F-Score | 2 |